Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243393 | 1.00 | SCD (0.78) | SCDSMN1; SMN2NPC1PIK3CDPIK3CA | |
| SCHEMBL1909537 | 0.89 | SCD (0.71) | SCDSMN1; SMN2NPC1 | |
| SCHEMBL243092 | 0.88 | SCD (1.00) | SCD | |
| SCHEMBL243091 | 0.88 | SCD (1.00) | SCD | |
| SCHEMBL1909622 | 0.78 | SCD (0.57) | SCDSMN1; SMN2 | |
| SCHEMBL348399 | 0.77 | PIK3CD (0.48) | SCDSMN1; SMN2NPC1PIK3CDPIK3CA | |
| SCHEMBL245185 | 0.74 | SCD (0.77) | SCDSMN1; SMN2PIK3CDPIK3CAPIK3CB | |
| SCHEMBL243706 | 0.72 | SCD (0.61) | SCDSMN1; SMN2NPC1PIK3CDPIK3CA | |
| SCHEMBL242203 | 0.71 | SCD (0.52) | SCDSMN1; SMN2NPC1PIK3CDPIK3CA | |
| SCHEMBL245141 | 0.70 | SCD (0.69) | SCDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885SMN1; SMN2 3878/4885NPC1 242/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885SMN1; SMN2 3581/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.